BioLineRx and Hemispherian will present preclinical data on GLIX1 at the 2026 European Society for Medical Oncology Annu...
Akeso has dosed the first patient in a Phase II clinical study evaluating AK146D1 in combination with ivonescimab for ad...
Halozyme Therapeutics has entered a global collaboration and licence agreement with Incyte to evaluate additional subcut...
Rege Nephro, a clinical-stage biotechnology startup focused on induced pluripotent stem (iPS) cell-based kidney regenera...
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have developed a ...
A “precision guided” CAR T-cell therapy designed at Peter MacCallum Cancer Centre, Australia’s on...
Canada-based ExCellThera Inc., a global leader in blood stem cell expansion and metabolic fitness technologies and paren...
Frederick Appelbaum, MD, executive vice president and professor in the clinical research division at Fred Hutch Cancer C...
US-based Organon, a global healthcare company with deep expertise in biosimilars, and Korea's Samsung Bioepis have annou...
Maxona Pharmaceuticals has received U.S. FDA clearance of its Investigational New Drug application for a Phase 2 clinica...
Lakewood-Amedex Biotherapeutics has announced preclinical safety data supporting clinical dose selection for its upcomin...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
The pharmaceutical industry’s innovation equation is changing. Developing an entirely new molecu...
As BioSpectrum Asia reports on the ground from BIO Asia–Taiwan 2026, being held from July 15–19 in T...
Versiti, Inc., a nonprofit organization dedicated to improving blood health for patients everywhere, has joined the Bloo...
MEDIPOST has treated the first U.S. participant in its Phase III clinical trial evaluating an investigational mesenchyma...
China-based startup OTR Therapeutics has entered into a strategic collaboration agreement with Korean company LG Chem to...
Artificial intelligence is rapidly reshaping the way biopharma companies discover, develop, and manufacture medicines. H...
RoosterBio and Qkine have entered a distribution agreement to provide U.S. customers with a single-source platform for c...
Catalent and Nanoscope Therapeutics have expanded their partnership to support late-phase clinical development and comme...
FibroBiologics has completed manufacturing of the third batch of CYWC628 drug product for its ongoing Phase 1/2 clinical...
Insilico Medicine has initiated a Phase III clinical trial of rentosertib, its AI-discovered oral small-molecule TNIK in...
REPROCELL has submitted an application for manufacturing and marketing approval in Japan for Stemchymal, a regenerative ...
As cell and gene therapies progress from promising research to commercial reality, manufacturing has emerged as ...
The rapid expansion of in vivo gene therapy is reshaping expectations for viral vector manufacturing, placing greater em...
